Related references
Note: Only part of the references are listed.The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response
Niamh Coleman et al.
BRITISH JOURNAL OF CANCER (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
Carl M. Gay et al.
CANCER CELL (2021)
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response
Sophie E. Willis et al.
BRITISH JOURNAL OF CANCER (2021)
Mechanisms of small cell lung cancer metastasis
Julie Ko et al.
EMBO MOLECULAR MEDICINE (2021)
Combination therapy: Future directions of immunotherapy in small cell lung cancer
Wei Huang et al.
TRANSLATIONAL ONCOLOGY (2021)
A Call to Action: Dismantling Racial Injustices in Preclinical Research and Clinical Care of Black Patients Living with Small Cell Lung Cancer
Portia L. Thomas et al.
CANCER DISCOVERY (2021)
YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes
Xin Wang et al.
LUNG CANCER (2021)
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer
Luckson Mathieu et al.
ONCOLOGIST (2021)
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair-targeted therapies
Camille Tlemsani et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
Yue Pan et al.
FRONTIERS IN ONCOLOGY (2021)
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review
Alessandro Leonetti et al.
FRONTIERS IN ONCOLOGY (2021)
Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung
Walter Z. Wang et al.
CELL DEATH & DISEASE (2021)
Angiogenesis Inhibitors in Small Cell Lung Cancer
Agnese Montanino et al.
FRONTIERS IN ONCOLOGY (2021)
The cGAS-STING pathway as a therapeutic target in inflammatory diseases
Alexiane Decout et al.
NATURE REVIEWS IMMUNOLOGY (2021)
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses
Taofeek K. Owonikoko et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
Hyun Cheol Chung et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate
Abbie S. Ireland et al.
CANCER CELL (2020)
NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration
Yuki Ikematsu et al.
LUNG CANCER (2020)
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
Ping-Chih Hsu et al.
CANCERS (2020)
Predictors of prognosis of synchronous brain metastases in small-cell lung cancer patients
Sumanth P. Reddy et al.
CLINICAL & EXPERIMENTAL METASTASIS (2020)
Cells of origin of lung cancers: lessons from mouse studies
Giustina Ferone et al.
GENES & DEVELOPMENT (2020)
Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets
Julia Krushkal et al.
CLINICAL EPIGENETICS (2020)
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases The FIRE-SCLC Cohort Study
Chad G. Rusthoven et al.
JAMA ONCOLOGY (2020)
ERK Regulates NeuroD1-mediated Neurite Outgrowth via Proteasomal Degradation
Tae-young Lee et al.
EXPERIMENTAL NEUROBIOLOGY (2020)
A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer
Michal Shreberk-Shaked et al.
CANCER RESEARCH (2020)
Developmental changes in the accessible chromatin, transcriptome and Ascl1-binding correlate with the loss in Muller Glial regenerative potential
Leah S. VandenBosch et al.
SCIENTIFIC REPORTS (2020)
SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization
Marina K. Baine et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy
Juyan Zheng et al.
MOLECULAR CANCER (2020)
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Yao Xiong et al.
NEOPLASIA (2020)
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn L. Simpson et al.
NATURE CANCER (2020)
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
C. Allison Stewart et al.
NATURE CANCER (2020)
c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL
Ho Yeon Lee et al.
MOLECULAR CANCER RESEARCH (2019)
Immunotherapy for small cell lung cancer: mechanisms of resistance
Gerhard Hamilton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Tuft cells: From the mucosa to the thymus
Shir Nevo et al.
IMMUNOLOGY LETTERS (2019)
Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death
Wei-Hsun Hsu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion
Milind D. Chalishazar et al.
CLINICAL CANCER RESEARCH (2019)
Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells
Yuki Tenjin et al.
INTERNAL MEDICINE (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer
Marcel A. Dammed et al.
NATURE COMMUNICATIONS (2019)
Systems-level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers
David J. Wooten et al.
PLOS COMPUTATIONAL BIOLOGY (2019)
EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Histologic transformation of ALK-rearranged adenocarcinoma to squamous cell carcinoma after treatment with ALK inhibitor
Sehhoon Park et al.
LUNG CANCER (2019)
Axon-like protrusions promote small cell lung cancer migration and metastasis
Dian Yang et al.
ELIFE (2019)
Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers
Carl M. Gay et al.
CLINICAL CANCER RESEARCH (2019)
Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
Charles M. Rudin et al.
NATURE REVIEWS CANCER (2019)
Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers
Fang Huang et al.
CELL METABOLISM (2018)
POU2F3 is a master regulator of a tuft cell-like variant of small cell lung cancer
Yu-Han Huang et al.
GENES & DEVELOPMENT (2018)
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Catherine Pietanza et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?
Charbel Hobeika et al.
PERSONALIZED MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Alex H. Wagner et al.
NATURE COMMUNICATIONS (2018)
Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression
Timothy L. Lochmann et al.
CLINICAL CANCER RESEARCH (2018)
Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes
Wei Zhang et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Transcriptional deregulation underlying the pathogenesis of small cell lung cancer
Dong-Wook Kim et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
Benjamin H. Lok et al.
CLINICAL CANCER RESEARCH (2017)
The Retinoblastoma (RB) Tumor Suppressor: Pushing Back against Genome Instability on Multiple Fronts
Renier Velez-Cruz et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
Charles M. Rudin et al.
LANCET ONCOLOGY (2017)
Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer
Jing Shan Lim et al.
NATURE (2017)
Unravelling the biology of SCLC: implications for therapy
Joshua K. Sabari et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
You-cai Zhu et al.
ONCOTARGETS AND THERAPY (2017)
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
Johann de Bono et al.
CANCER DISCOVERY (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
State-of-the-art considerations in small cell lung cancer brain metastases
Rimas V. Lukas et al.
ONCOTARGET (2017)
Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies
Robert J. Cardnell et al.
ONCOTARGET (2017)
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
C. Allison Stewart et al.
ONCOTARGET (2017)
Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer
Fabian Doerr et al.
SCIENTIFIC REPORTS (2017)
New insights into stage and prognosis in small cell lung cancer: an analysis of 968 cases
Charles Dayen et al.
JOURNAL OF THORACIC DISEASE (2017)
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
Triparna Sen et al.
CLINICAL CANCER RESEARCH (2017)
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib
Triparna Sen et al.
CANCER RESEARCH (2017)
Racial and Ethnic Disparities in Health Insurance Coverage: Dynamics of Gaining and Losing Coverage Over the Life-Course
Heeju Sohn
POPULATION RESEARCH AND POLICY REVIEW (2017)
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis
Eric E. Gardner et al.
CANCER CELL (2017)
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
Gurkan Mollaoglu et al.
CANCER CELL (2017)
Tuft-cell-derived IL-25 regulates an intestinal ILC2-epithelial response circuit
Jakob von Moltke et al.
NATURE (2016)
Notch1 controls cell chemoresistance in small cell lung carcinoma cells
Wael Abdo Hassan et al.
THORACIC CANCER (2016)
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib
N. Takegawa et al.
ANNALS OF ONCOLOGY (2016)
Loss of YAP1 defines neuroendocrine differentiation of lung tumors
Takeshi Ito et al.
CANCER SCIENCE (2016)
YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer
Masafumi Horie et al.
CANCER SCIENCE (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Histological transformation of ALK rearranged adenocarcinoma into small cell lung cancer: A new mechanism of resistance to ALK inhibitors
Delphine Levacq et al.
LUNG CANCER (2016)
Small cell lung cancer: Time to revisit DNA-damaging chemotherapy
Anish Thomas et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Vasculogenic mimicry in small cell lung cancer
Stuart C. Williamson et al.
NATURE COMMUNICATIONS (2016)
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai et al.
ONCOTARGET (2016)
ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs
Mark D. Borromeo et al.
CELL REPORTS (2016)
Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis
Min-chul Kwon et al.
GENES & DEVELOPMENT (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Lineage factors and differentiation states in lung cancer progression
W. K. C. Cheung et al.
ONCOGENE (2015)
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
Laura R. Saunders et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Ascl1 Coordinately Regulates Gene Expression and the Chromatin Landscape during Neurogenesis
Alexandre A. S. F. Raposo et al.
CELL REPORTS (2015)
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Patricia A. J. Muller et al.
CANCER CELL (2014)
ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers
Alexander Augustyn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
BMN673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
Yuqiao Shen et al.
CLINICAL CANCER RESEARCH (2013)
Small Cell Lung Cancer
Gregory P. Kalemkerian et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2013)
Mutational landscape and significance across 12 major cancer types
Cyriac Kandoth et al.
NATURE (2013)
NeuroD1 regulates survival and migration of neuroendocrine lung carcinomas via signaling molecules TrkB and NCAM
Jihan K. Osborne et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Development of mice without Cip/Kip CDK inhibitors
Yuki Tateishi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications
Dawn A. Kirschmann et al.
CLINICAL CANCER RESEARCH (2012)
Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cells
Mitsuru Morimoto et al.
DEVELOPMENT (2012)
MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors
Aatur D. Singhi et al.
MODERN PATHOLOGY (2012)
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer
Charles M. Rudin et al.
NATURE GENETICS (2012)
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Martin Peifer et al.
NATURE GENETICS (2012)
Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis
Hai Song et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Functional Role for Tumor Cell Heterogeneity in a Mouse Model of Small Cell Lung Cancer
Joaquim Calbo et al.
CANCER CELL (2011)
Cell of Origin of Small Cell Lung Cancer: Inactivation of Trp53 and Rb1 in Distinct Cell Types of Adult Mouse Lung
Kate D. Sutherland et al.
CANCER CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Characterization of the cell of origin for small cell lung cancer
Kwon-Sik Park et al.
CELL CYCLE (2011)
Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis
Gavin Chapman et al.
HUMAN MOLECULAR GENETICS (2011)
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer A Brief Report
Tsu-Hui Shiao et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma
M. E. Kupferman et al.
ONCOGENE (2010)
Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer
Tianyun Jiang et al.
CANCER RESEARCH (2009)
Notch signaling controls the balance of ciliated and secretory cell fates in developing airways
Po-Nien Tsao et al.
DEVELOPMENT (2009)
Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube
R. Michael Henke et al.
DEVELOPMENTAL BIOLOGY (2009)
Cytoplasmic functions of the tumour suppressor p53
Douglas R. Green et al.
NATURE (2009)
Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results
Isao Oze et al.
PLOS ONE (2009)
Tumor Suppressive Functions of p53
Jack T. Zilfou et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2009)
CDK inhibitors: Cell cycle regulators and beyond
Arnaud Besson et al.
DEVELOPMENTAL CELL (2008)
Transcriptional control of human p53-regulated genes
Todd Riley et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2008)
Tumor suppressor LATS1 is a negative regulator of oncogene YAP
Yawei Hao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Cellular mechanisms of tumour suppression by the retinoblastoma gene
Deborah L. Burkhart et al.
NATURE REVIEWS CANCER (2008)
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
Bin Zhao et al.
GENES & DEVELOPMENT (2007)
Notch and cancer: a double-edged sword
U. Koch et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
TRPM5, a taste-signaling transient receptor potential ion-channel, is a ubiquitous signaling component in chemosensory cells
Silke Kaske et al.
BMC NEUROSCIENCE (2007)
The p53 tumor suppressor participates in multiple cell cycle checkpoints
Luciana E. Giono et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
The dual specificity phosphatase cdc25C is a direct target for transcriptional repression by the tumor suppressor p53
Selvon St. Clair et al.
CELL CYCLE (2006)
ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features
H Osada et al.
CANCER RESEARCH (2005)
The mysterious pulmonary brush cell - A cell in search of a function
L Reid et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model
R Meuwissen et al.
CANCER CELL (2003)
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
M Narita et al.
CELL (2003)
Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis
S Basu et al.
MOLECULAR CELL (2003)
N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling
U Cavallaro et al.
NATURE CELL BIOLOGY (2001)
The retinoblastoma gene: A prototypic and multifunctional tumor suppressor
L Zheng et al.
EXPERIMENTAL CELL RESEARCH (2001)
Share Paper
